Compare

Viskase Holdings, Inc. vs Scilex Holding Co vs Monte Rosa Therapeutics, Inc. vs Vor Biopharma Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearViskase Holdings, Inc.
VISKRevenue covers only part of its income (partial revenue)
Scilex Holding Co
SCLXRevenue covers only part of its income (partial revenue)
Monte Rosa Therapeutics, Inc.
GLUE
Vor Biopharma Inc.
VOR
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$30.25M$123.67Mn/a
Revenue growth (YoY)n/a-46.5%+63.5%n/a
Gross marginn/a65.0% (computed)n/an/a
Operating marginn/an/m-43.8%n/a
Net marginn/an/m-31.2%n/a
Net income-$3.41M-$374.05M-$38.63M-$695.98M
EPS (Diluted)-$0.07-$36.48n/a-$70.50
Operating cash flow-$3.01M$3.82M-$22.80M-$142.71M
Free cash flown/a$3.68M-$27.50M-$143.65M
Cash & equivalents$42.57M$4.96M$129.88M$396.49M
Total assets$42.81M$364.98M$448.66M$464.13M
Total liabilitiesn/a$576.73M$215.60M$628.44M
Shareholders' equity-$2.52M-$207.78M$233.06M-$164.31M
Return on year-end equityn/an/a-16.6%n/a
Shares outstanding74.21M7.03M65.54M38.72M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearViskase Holdings, Inc.Scilex Holding CoMonte Rosa Therapeutics, Inc.Vor Biopharma Inc.
Latestn/an/a$123.67M
Ended 2025-12-31
n/a
1 year earliern/an/a$75.62M
Ended 2024-12-31
n/a
2 years earliern/an/a$0
Ended 2023-12-31
n/a
3 years earliern/an/an/an/a
4 years earliern/an/an/an/a